Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: ROIV

Roivant Sciences Ltd.

Healthcare | Biotechnology

No licensed closing price on file for ROIV. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-0.47

Roivant Sciences Ltd. (NASDAQ: ROIV) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 16:47 UTC.

What Roivant Sciences Ltd. does

Roivant is a biopharmaceutical company that develops medicines by creating independent subsidiaries called Vants, each focused on specific drug candidates and therapeutic areas. The company's pipeline includes brepocitinib for inflammatory and autoimmune conditions, IMVT-1402 for various IgG-mediated autoimmune diseases, and mosliciguat for pulmonary hypertension. Roivant identifies and in-licenses promising drug candidates through its business development network, then allocates capital centrally while empowering Vant teams with operational decision-making authority and equity incentives.

Summarized from Roivant Sciences Ltd.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-0.47

Revenue, margins & earnings

FY2022: net loss $845M on revenue $55M$55MFY2022FY2023: net loss $1.01B on revenue $32M$32MFY2023FY2024 Revenue: $33M — margin split not shown (non-operating gains)FY2024: net income $4.35B exceeded revenue $33M by $4.32B — non-operating gains (e.g. asset sales), not operating profit$33MFY2024FY2025: net loss $172M on revenue $29M$29MFY2025FY2026: net loss $300M on revenue $8M$8MFY2026
  • Net income
  • Taxes & interest
  • Operating costs
  • Net income above revenue (non-operating gains)
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →
Gold cap: net income exceeded revenue that year from non-operating gains (e.g. asset sales), not operating profit.

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-05
  • 2026-10-05DirectorOption exercise17,750$79.2K
  • 2026-10-05DirectorSale-16,850$607.9K
  • 2026-10-05DirectorStock Option (Right to Buy)Option exercise-17,750—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Roivant Sciences Ltd. do?

Roivant is a biopharmaceutical company that develops medicines by creating independent subsidiaries called Vants, each focused on specific drug candidates and therapeutic areas.

When did ROIV last file with the SEC?

Roivant Sciences Ltd.'s most recent SEC filing on record is a 10-K filed 2026-05-20. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 16:47 UTC. This page is also available as JSON at /api/data?ticker=ROIV and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for ROIV and 5,000+ tickers.

Create a free account — keep ROIV
For your agent
GET /api/data?ticker=ROIV

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt